Leukocyte-Reduced Red Blood Cells and Platelets are indicated for which patient group?

Leukocyte-reduced red blood cells and platelets are specifically indicated for patients with a history of febrile transfusion reactions. These reactions are often caused by antibodies against donor leukocytes, leading to the patient's immune response when receiving blood products. By using leukocyte-reduced blood components, the number of white blood cells is significantly decreased, minimizing the potential for these febrile reactions to occur again.

In the context of the other groups mentioned, while they may have distinct blood product needs, they do not specifically require leukocyte-reduced components as a standard or necessary precaution. For example, postpartum mothers and burn victims may have specific needs related to their conditions, but leukocyte reduction is less relevant for their typical treatment protocols. Similarly, victims of acute trauma might benefit from transfusions, but the concerns regarding febrile reactions are not their primary consideration. Thus, the tailored approach of leukocyte reduction specifically benefits those with prior transfusion reactions by addressing the risk of similar occurrences.